Relapsed hairy cell leukemia 37
53. Dearden CE, Matutes E, Hilditch BL, et al. Long-term follow- 61. Ravandi F, Jorgensen JL, O’Brien SM, et al. Eradication of
up of patients with hairy cell leukaemia after treatment with minimal residual disease in hairy cell leukemia. Blood
pentostatin or cladribine. Br J Haematol 1999;106:515–519. 2006;107:4658–4662.
54. Rafel M, Cervantes F, Beltran JM, et al. Deoxycoformycin in 62. Else M, Osuji N, Forconi F, et al. The role of rituximab in
the treatment of patients with hairy cell leukemia: results of a combination with pentostatin or cladribine for the treatment of
Spanish collaborative study of 80 patients. Cancer 2000;88: recurrent/refractory hairy cell leukemia. Cancer 2007;110:
352–357. 2240–2247.
55. Habermann TM. Splenectomy, interferon, and treatments of 63. Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as
historical interest in hairy cell leukemia. Hematol Oncol Clin treatment for minimal residual disease in hairy cell leukaemia.
North Am 2006;20:1075–1086. Eur J Haematol 2004;73:412–417.
56. Zakarija A, Peterson LC, Tallman MS. Splenectomy and 64. Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as
treatments of historical interest. Best Pract Res Clin Haematol treatment for minimal residual disease in hairy cell
2003;16:57–68. leukaemia: extended follow-up. Br J Haematol 2008;143:
57. Dunn P, Shih LY, Ho YS, et al. Hairy cell leukemia variant. 296–298.
Acta Haematol 1995;94:105–108. 65. Bastie JN, CazalsHatem D, Daniel MT, et al. Five years
58. Nishii K, Katayama N, Maeda H, et al. Successful treatment follow-up after 2-chloro deoxyadenosine treatment in thirty
with low-dose splenic irradiation for massive splenomegaly in patients with hairy cell leukemia: evaluation of minimal
an elderly patient with hairy-cell leukemia. Eur J Haematol residual disease and CD4þlymphocytopenia after treatment.
2001;67:255–257. Leuk Lymphoma 1999;35:555–565.
59. Gidron A, Tallman MS. Hairy cell leukemia: towards a curative 66. Wheaton S, Tallman MS, Hakimian D, et al. Minimal
strategy. Hematol Oncol Clin North Am 2006;20:1153–1162. residual disease may predict bone marrow relapse in patients
60. Fanta PT, Saven A. Hairy cell leukemia. Cancer Treat Res with hairy cell leukemia treated with 2-chlorodeoxyadenosine.
2008;142:193–209. Blood 1996;87:1556–1560.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46